Featured Research

from universities, journals, and other organizations

New hepatitis C drug shows potential in phase 2 trials

Date:
October 10, 2013
Source:
American Gastroenterological Association
Summary:
The addition of danoprevir to the current treatment regimen for patients with hepatitis C leads to high rates of remission, according to a new article.

The addition of danoprevir to the current treatment regimen for patients with hepatitis C leads to high rates of remission, according to a new article in Gastroenterology, the official journal of the American Gastroenterological Association. The current standard of care for hepatitis C patients includes a combination of peginterferon and ribavirin.

"Despite recent advances, the current hepatitis C treatment regimen is burdensome on the patient and prone to adverse events," said Patrick Marcellin, lead study author from the Service d'Hépatologie and Inserm CRB3, Hôpital Beaujon, APHP University of Paris. "The promising results from this study offer hope that danoprevir can improve the quality of life for patients suffering from this disease."

Investigators conducted a phase 2, randomized, placebo-controlled study and found that, within just one week of treatment, the addition of danoprevir to the current treatment regimen (peginterferon alfa-2a/ribavirin) led to reductions in levels of hepatitis C virus in the blood. Overall, danoprevir was well tolerated and demonstrated an 85 percent sustained virologic response rate (or no detectable virus in the patient's blood after six months).

Importantly, 79 percent of patients who added danoprevir to their treatment regimen achieved an early virologic response and were eligible for a shortened treatment schedule.

Studies of lower doses of danoprevir on top of the current standard of care, to reduce overall danoprevir exposure while maintaining the drug's effectiveness, are underway. Interim effectiveness and safety data are promising.

Hepatitis C is a serious liver disease caused by the hepatitis C virus, which is spread through direct contact with the blood of infected people and ultimately affects the liver. Chronic hepatitis C can lead to serious and life-threatening liver problems, including liver damage, cirrhosis, liver failure or liver cancer. Though many people with hepatitis C may not experience symptoms, others may have symptoms such as fatigue, fever, jaundice and abdominal pain. For more information on hepatitis, please read the AGA brochure "Understanding Hepatitis."


Story Source:

The above story is based on materials provided by American Gastroenterological Association. Note: Materials may be edited for content and length.


Journal Reference:

  1. Patrick Marcellin, Curtis Cooper, Luis Balart, Dominique Larrey, Terry Box, Eric Yoshida, Eric Lawitz, Peter Buggisch, Peter Ferenci, Martin Weltman, Emily Labriola–Tompkins, Sophie Le Pogam, Isabel Nájera, Denise Thomas, Gregory Hooper, Nancy S. Shulman, Ying Zhang, Mercidita T. Navarro, Chin Yin Lim, Michael Brunda, Norah A. Terrault, Ellen S. Yetzer. Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection. Gastroenterology, 2013; 145 (4): 790 DOI: 10.1053/j.gastro.2013.06.051

Cite This Page:

American Gastroenterological Association. "New hepatitis C drug shows potential in phase 2 trials." ScienceDaily. ScienceDaily, 10 October 2013. <www.sciencedaily.com/releases/2013/10/131010105117.htm>.
American Gastroenterological Association. (2013, October 10). New hepatitis C drug shows potential in phase 2 trials. ScienceDaily. Retrieved September 2, 2014 from www.sciencedaily.com/releases/2013/10/131010105117.htm
American Gastroenterological Association. "New hepatitis C drug shows potential in phase 2 trials." ScienceDaily. www.sciencedaily.com/releases/2013/10/131010105117.htm (accessed September 2, 2014).

Share This




More Health & Medicine News

Tuesday, September 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

Newsy (Sep. 2, 2014) — The U.N. says the problem is two-fold — quarantine zones and travel restrictions are limiting the movement of both people and food. Video provided by Newsy
Powered by NewsLook.com
Get on Your Bike! London Cycling Popularity Soars Despite Danger

Get on Your Bike! London Cycling Popularity Soars Despite Danger

AFP (Sep. 1, 2014) — Wedged between buses, lorries and cars, cycling in London isn't for the faint hearted. Nevertheless the number of people choosing to bike in the British capital has doubled over the past 15 years. Duration: 02:27 Video provided by AFP
Powered by NewsLook.com
Can You Train Your Brain To Eat Healthy?

Can You Train Your Brain To Eat Healthy?

Newsy (Sep. 1, 2014) — New research says if you condition yourself to eat healthy foods, eventually you'll crave them instead of junk food. Video provided by Newsy
Powered by NewsLook.com
We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) — A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins